{"id":"adalimumab-european-source","safety":{"commonSideEffects":[{"rate":"10%","effect":"Injection site reaction"},{"rate":"10%","effect":"Headache"},{"rate":"10%","effect":"Fatigue"},{"rate":"5%","effect":"Nausea"},{"rate":"5%","effect":"Diarrhea"}]},"_chembl":{"chemblId":"CHEMBL1201580","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Adalimumab is a fully human monoclonal antibody that selectively binds to human tumour necrosis factor-alpha (TNF-alpha) and inhibits its interaction with cell surface TNF receptors. This action prevents the downstream effects of TNF-alpha, including inflammation and cytotoxicity.","oneSentence":"Tumour necrosis factor-alpha inhibitor","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T05:49:22.513Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rheumatoid Arthritis"},{"name":"Psoriatic Arthritis"},{"name":"Ankylosing Spondylitis"},{"name":"Crohn's Disease"},{"name":"Ulcerative Colitis"}]},"trialDetails":[{"nctId":"NCT03254810","phase":"PHASE1","title":"Comparison of the Safety and PK of SYN060 to Humira® in Healthy Adult Subjects","status":"COMPLETED","sponsor":"Synermore Biologics Co., Ltd.","startDate":"2017-09-26","conditions":"Arthritis, Rheumatoid","enrollment":94}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_1","status":"active","brandName":"Adalimumab European source","genericName":"Adalimumab European source","companyName":"Synermore Biologics Co., Ltd.","companyId":"synermore-biologics-co-ltd","modality":"Biologic","firstApprovalDate":"","aiSummary":"Tumour necrosis factor-alpha inhibitor Used for Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}